Across TCGA pan-cancer cohorts, RNY4P6 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated RNY4P6 data layer.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNY4P6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNY4P6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CESC show a favorable association.
CHOL, HNSC, and KIRP are the cancer types where RNY4P6 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.